---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dialysis"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dialysis. Topics: Timing of dialysis initiation: KDIGO 2024 CKD guideline, Initial kidney replacement therapy modality and age at treatment start in the United States, and Age at hemodialysis initiation by APOL1 genotype. 3 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/dialysis"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dialysis

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Dialysis

<a id="topic-2.2.2.1.7-1"></a>

### Timing of dialysis initiation: KDIGO 2024 CKD guideline

> “Practice Point 5.4.1: Initiate dialysis based on a composite assessment of a person’s symptoms, signs, QoL, preferences, level of GFR, and laboratory abnormalities.”
> “This often but not invariably occurs in the GFR range between 5 and 10 ml/min per 1.73 m2.”
> “Practice Point 5.5.1: Inform people with CKD about the options for KRT and comprehensive conservative care.”

Source: [KDIGO (2024)](https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf)

<a id="topic-2.2.2.1.7-2"></a>

### Initial kidney replacement therapy modality and age at treatment start in the United States

> “Although in-center HD remained the most common initial ESKD treatment modality in 2023 (81.7%), there was a shift toward PD over the last decade. The percentage starting PD reached an all-time high of 14.1% in 2023. Preemptive kidney transplant also reached a new high, though it remained only 3.8% in 2023.”
> “Black, Hispanic, Native American, and Native American and Other Pacific Islander people started treatment for ESKD at a younger age (median 59-62 years) than White and Asian people (median 66-68 years).”

Source: [USRDS Annual Data Report, ESKD incidence and prevalence (2025)](https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/1-incidence-and-prevalence)

<a id="topic-2.2.2.1.7-3"></a>

### Age at hemodialysis initiation by APOL1 genotype

> “African Americans carrying two copies of the G1 risk allele initiated chronic hemodialysis at a mean age of 49.0 ± 14.9 years, which was significantly younger than both subjects with one copy of the G1 allele (55.9 ± 16.7 years; P = 0.014) and subjects without either risk allele (61.8 ± 17.1 years; P = 6.2 × 10−7).”

Source: [Kanji et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231784/)

> “People with AMKD progress to end stage kidney disease at a faster rate than those with other forms of chronic kidney disease and reach kidney failure at a median age of 45 years old.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
